Wegovy pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

• Approval is based on results from the OASIS 4 trial, which investigated semaglutide tablets 25 mg in adults living with obesity and overweight versus placebo in addition to diet and exercise
• Semaglutide tablets will be available as a once-daily treatment, an alternative to weekly injections for adults living with obesity or overweight with a weight-related condition, alongside diet and exercise
• After this approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), Novo Nordisk anticipates Wegovy pill will be available via private prescription within weeks

Bagsværd, Denmark, 11 June 2026 – Wegovy pill, the new daily weight management tablet, has been approved in the UK as an adjunct to a reduced-calorie diet and increased physical activity, offering a first-of-its-kind alternative to injectable treatments for adults.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wegovy pill (semaglutide tablets), an oral glucagon-like peptide-1 (GLP-1) receptor agonist licensed for weight management in adults living with obesity (initial Body Mass Index (BMI) ≥30 kg/m2), or overweight (BMI ≥27 kg/m2 to <30 kg/m2), with at least one weight-related condition.

The MHRA approval is based on data from the OASIS 4 phase 3 clinical trial. When evaluating the effect of treatment regardless of adherence, adults with obesity receiving semaglutide tablets 25 mg achieved ~14% (13.6%) weight loss vs ~2% (2.4%) with placebo after 64 weeks, in addition to lifestyle modifications. Results showed that if all participants adhered to treatment, semaglutide 25 mg achieved weight loss of ~17% (16.6%) vs ~3% (2.7%) placebo after 64 weeks.

The study evaluated semaglutide tablets 25 mg in 307 adults with obesity or overweight with at least one weight-related condition, without diabetes. In the study, the most commonly reported side effects were gastrointestinal, including nausea, vomiting and diarrhoea, reported by 74.0% participants in the oral semaglutide group and by 42.2% in the placebo group, respectively. These side effects were generally mild to moderate and transient. In OASIS 4, adverse events leading to treatment discontinuation occurred in ~7% (6.9%) of participants receiving oral semaglutide, which is consistent with rates observed in trials of injectable semaglutide.

Schreibe Deinen Kommentar